Company Overview and News
Spectrum Pharmaceuticals, Inc. (SPPI - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because SPPI recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
The bioscience market traded slightly south with an overall skittish sentiment. Despite some key losers, many equities under our coverage continued to break the trend to post further gains.
CDTX MYL PRTK SPPI MDCO MLNT IBB AKAO XBI NVAX
As a promising grower, OncoMed is leveraging on the “more shots on goal” strategy. Despite earlier missed clinical outcomes, the company is brewing stellar molecules that are approaching their binaries.
OMED EXEL CELGZ SPPI CELG
Ultragenyx (NASDAQ:RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; and another approval of borosumab (Crysvita) in April - which also happened. We also liked its cash position, both then and now, and its sale of a Rare Disease Priority Review voucher for $130mn.
NERV AMGN EXEL SPPI RARE PFE SNDX
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported first-quarter 2018 adjusted earnings of $1.55 per share, significantly up from the year-ago figure of 57 cents. The bottom line also beat the Zacks Consensus Estimate of $1.28.
GLENMARK AMGN SPPI MLNT LGNDZ GLKQY SAGE 532296 GM.WS.A GM.WS.B LGNZZ LGND GM.WS.C LGNYZ NVS LGNXZ GM GM.WSB
Document Table of Contents UNITED STATES
Spectrum Pharmaceuticals, Inc. (SPPI - Free Report) incurred a loss of 16 cents per share in the first quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago quarter loss of 30 cents per share. However, adjusted loss came in at 15 cents, wider-than the year ago loss of 14 cents.
AMGN CACU SPPI ARW LGNZZ LGND LGNYZ CACI LGNXZ PTGX LGNDZ
Good day, ladies and gentlemen, and welcome to Spectrum Pharmaceuticals First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, today’s conference is being recorded.
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to SPPI / Spectrum Pharmaceuticals, Inc. on message board site Silicon Investor.
|Spectrum Pharmaceuticals, Inc (SPPI)||Spectrum|
as of ET